JERSEY
CITY, N.J., April 28,
2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an
agreement with Express Scripts, one of the nation's leading
pharmacy benefit managers (PBMs) negotiating on behalf of health
plans covering more than 100 million people. The agreement,
effective April 4, 2024 provides
ZYMFENTRA Preferred Brand Access on the Express Scripts National
Preferred Formulary serving 21.9 Million insured lives. Express
Scripts provides plan participants such as Health Plans of
the PBM the ability to add
ZYMFENTRA™ (infliximab-dyyb) to their formularies.
"This agreement opens up an important pathway for access to
treatment for millions of patients with chronic diseases," said
Francine Galante, Vice President of
Market Access at Celltrion USA.
"We will continue to work with providers, patients and physicians
to build upon our mission of developing transformational therapies
that meet the needs of our patients living with chronic
debilitating pain."
Celltrion's ZYMFENTRA, the first and only
FDA-approved subcutaneous infliximab is now commercially available
in the U.S.
The company continues to engage with national and regional
health plans, as well as Pharmacy Benefit Managers (PBMs) and Group
Purchasing Organizations (GPOs), to communicate the value of its
FDA-approved therapies including ZYMFENTRA for patients with
autoimmune disease and to secure broad coverage.
About Celltrion USA
Celltrion USA is Celltrion's
U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to
innovative biologics to improve care for U.S. patients. Celltrion
currently has five biosimilars approved by the U.S. FDA:
INFLECTRA® (infliximab-dyyb),
TRUXIMA® (rituximab-abbs),
HERZUMA® (trastuzumab-pkrb),
VEGZELMA® (bevacizumab-adcd), and
YUFLYMA®(adalimumab-aaty) as well as a new biologic
ZYMFENTRA™. Celltrion USA will
continue to leverage Celltrion's unique heritage in biotechnology,
supply chain excellence, and best-in-class sales capabilities to
improve access to high-quality biopharmaceuticals for U.S.
patients. For more information, please visit:
www.celltrionusa.com/.
About
ZYMFENTRA™ (infliximab-dyyb)[1]
ZYMFENTRA is a prescription medicine used as an injection under
the skin (subcutaneous injection) by adults for the maintenance
treatment of: moderately to severely active ulcerative colitis
following treatment with an infliximab product given by intravenous
infusion (IV), moderately to severely active Crohn's disease
following treatment with an infliximab product given by intravenous
infusion (IV). ZYMFENTRA blocks the action of tumor necrosis
factor-alpha (TNF-alpha), a protein that can be overproduced in
response to certain diseases and cause the immune system to attack
normal, healthy parts of the body.
ZYMFENTRA™ (infliximab-dyyb) was approved by the FDA through the
Biologics License Application (BLA) under the 351 (a) pathway of
the Public Health Service Act (a "stand-alone" BLA). ZYMFENTRA is
considered a new biologic with a first-approved subcutaneous
administration form and thus will be under patent protection for
its dosage form by 2037 and for its route of administration by
2040.
[1] Zymfentra
Prescribing Information
|
Contacts
Sarah
Amundsen
samundsen@apcoworldwide.com
+1 920-946-0918
View original content to download
multimedia:https://www.prnewswire.com/news-releases/celltrion-usa-signs-agreement-with-express-scripts-for-its-therapy-for-autoimmune-diseases-including-the-first-fda-approved-subcutaneous-infliximab-zymfentra-302129482.html
SOURCE Celltrion USA